GerbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer

GerbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer

Autor Logullo, Angela Flavia Autor UNIFESP Google Scholar
Lopes, Andréa Braga de Godoy Google Scholar
Nonogaki, Suely Google Scholar
Soares, Fernando Augusto Google Scholar
Mourão Netto, Mario Google Scholar
Nishimoto, Inês Nobuko Google Scholar
Brentani, Maria Mitzi Autor UNIFESP Google Scholar
Instituição Universidade de São Paulo (USP)
Hosp Canc
Inst Adolfo Lutz Registro
Universidade Federal de São Paulo (UNIFESP)
Resumo The definition of high risk patients with early stage breast cancer is still controversial. We evaluated the ability of galectin-3, c-erbB-2 and p53 immunohistochemical expression to predict recurrence and survival in a homogeneous set of 92 patients with T1N0M0 ductal carcinoma with a long-term follow-up. In normal breast tissue, the epithelial and fibroblast components were positive for galectin-3 mostly showing nuclear and cytoplasmic reactivity. At the tumor epithelial component, galectin-3 expression was found in 46.7% of the samples with a predominant cytoplasmic staining. Similar results were presented by concurrent in situ lesions. Tumor stromal fibroblasts maintained positivity in 70 out of 92 cases (76%). We found expression of p53 in only 16 cases (17.4%), and c-erbB-2 in 17 (18.48%). A marginal association was found between co-expression of p53 and galectin-3 (p=0.055) and a significant correlation between p53 accumulation and c-erbB-2 expression (p=0.009). There was no significant association between (galectin-3 protein expression with disease-free survival or overall survival. C-erbB2 and p53 expression correlated with recurrence (p=0.002, p=0.02; respectively). Diminished overall survival at 10 years was associated with c-erbB-2 (p=0.010), but marginally with p53 expression (p=0.076). Epithelial galectin-3 expression cannot be considered a prognostic factor for patients with T1N0M0 breast cancer, p53 seems to be of minor relevance and c-erbB-2 expression was the best discriminator and may be a marker for aggressive clinical behavior in patients with early stage breast cancer.
Assunto breast carcinoma
T1N0M0
c-erbB-2
p53
galectin-3
immunohistochemistry
survival
disease-free survival
prognosis
Idioma Inglês
Data 2007-07-01
Publicado em Oncology Reports. Athens: Professor D A Spandidos, v. 18, n. 1, p. 121-126, 2007.
ISSN 1021-335X (Sherpa/Romeo, fator de impacto)
Editor Professor D A Spandidos
Extensão 121-126
Fonte http://dx.doi.org/10.3892/or.18.1.121
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000247629900019
URI http://repositorio.unifesp.br/11600/45063

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)